Biological differences between men and women can have an impact on the success of melanoma treatment, according to new research co-led by Alfred oncologist Miles Andrews.
2022
Merck posts early clinical data on subcutaneous Keytruda, setting stage for further studies
Merck has presented early clinical data on subcutaneous formulations of its blockbuster checkpoint inhibitor Keytruda. The data drop is an early step in an ongoing effort to reformulate Keytruda ahead of the anticipated expiration of U.S. patents in 2028.
Skin cancer cells harness nerve cell gene to drill through and invade new tissues
Melanoma skin cancer cells harness a gene usually used by growing nerves to escape from their immediate area and spread through tissues, new research has found.
Immunocore wins FDA nod for first uveal melanoma treatment, also first T-cell receptor therapeutic
Uveal melanoma, an aggressive cancer of the eye, has been a particularly tough nut to crack for scientists trying to find a treatment.